

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/863,841
		Filing Date	May 22, 2001
		First Named Inventor	Kirkegaard, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet 2 of 4		Attorney Docket Number	STAN-193


OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MUS		DIAMOND, et al. "Clustered charged-to-alanine mutagenesis of poliovirus RNA-dependent RNA polymerase yields multiple temperature-sensitive mutants defective in RNA synthesis", <i>J. Virology</i> , (1994) Vol. 68(2): 863-876.	
		DOMINGO, et al. "Basic concepts in RNA virus evolution", <i>FASEB</i> , (1996) Vol. 10: 859-864.	
		DOUBLIÉ, et al. "The mechanism of action of T7 DNA polymerase", <i>Curr. Opin. Struct. Biol.</i> , (1998) Vol. 8: 704-712.	
		DOWNING, et al. "Tubulin and microtubule structure", <i>Curr. Opin. Cell Biol.</i> , (1998) Vol. 10: 16-22.	
		GRUN, et al. "Dissociation of NS5 from Cell Fractions Containing West Nile Virus-Specific Polymerase Activity", <i>J. Virol.</i> , (1987) Vol. 61: 3641-3644.	
		GYURIS, et al. "Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2", <i>Cell</i> , (1993) Vol. 791-803.	
		HANSEN, et al. "Structure of the RNA-dependent RNA polymerase of poliovirus", <i>Structure</i> , (1997) Vol. 5: 1109-1122.	
		HOPE, et al. "Genetic Dissection of Interaction between Poliovirus #D polymerase and Viral Protein 3AB", <i>J. Virol.</i> , (1997) Vol. 71: 9490-9498.	
		JACOBO-MOLINA, et al. "Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA", <i>Proc. Natl. Acad. Sci. USA</i> , (1993) Vol. 90: 6320-6324.	
		JANIN, et al. "Protein-protein interaction at crystal contacts", <i>Proteins</i> , (1995) Vol. 23: 580-587.	
		KAO, et al. "Brome Mosaic Virus RNA Replication Proteins 1a and 2a Form a Complex In Vitro", <i>J. Virol.</i> , (1992) Vol. 66: 6322-6329.	
		KIRKEGAARD. "Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA", <i>J. Virology</i> , (1990) Vol. 64(1): 195-206.	
		KOIKE, et al. "Transgenic mice susceptible to poliovirus", <i>Proc. Natl. Acad. Sci. USA</i> , (1991) Vol. 88: 951-955.	
		LEDLEY. "Pharmaceutical approach to somatic gene therapy", <i>Pharm. Res.</i> , (1996) Vol. 13(11): 1595-1614.	
MUS		LEMM, et al. "Assembly of functional sindbis virus RNA replication complexes: Requirement for coexpression of P123 and P34", <i>J. Virology</i> , (1993) Vol. 67(4): 1905-1915.	

Examiner Signature		Date Considered	03/2004
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/863,841
		Filing Date	May 22, 2001
		First Named Inventor	KIRKEGAARD, KARLA
		Art Unit	1631
Sheet 1 of 1	Examiner Name	BORIN, MICHAEL L.	
	Attorney Docket Number	STAN-193	

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ² -Number ² -Kind Code ² (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MS		Gohara et al., "Poliovirus RNA-dependent RNA Polymerase (3D ^{pol}). The Journal of Biological Chemistry, vol. 275, No. 33, pp 25523-32 (2000)	
		Hobson et al., "Oligomeric structures of poliovirus polymerase are important for function." The EMBO Journal, vol. 20, No. 5, pp. 1153-1163 (2001)	
MS		O'Reilly et al., "Analysis of RNA-dependent RNA Polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure." Virology 252, 287-303 (1998)	

Examiner Signature		Date Considered	03/2004
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.